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Dr. David Baker and His Contributions to the Fight Against SARS-CoV-2
We have been in the midst of a global pandemic for the last year and scientists have been hard at work trying to develop new technologies to combat
coronavirus. Dr. David Baker and researchers at the Institute for Protein Design worked on designing picomolar SARS-CoV-2 miniprotein inhibitors. 
Dr. Baker works on understanding protein structure and function through computer programs he has designed. These programs  used  were in attempts
to synthesize a drug to stop the spike proteins on the surface of coronavirus from infecting the human respiratory system.
Dr. Baker Lab’s Process for Designing Miniproteins to Combat Coronavirus:
Goal: To design high-
affinity protein 
minibinders to the 
coronavirus spike 
receptor binding domain 
[2].
Strategy 1: Incorporate an alpha helix 
from the human receptor into small 
proteins that would interact with the 
spike receptor binding domain to 
achieve higher affinity. A Rosetta 
blueprint builder was used to generate 
some miniproteins that incorporated 
the human alpha helix [2]. 
Strategy 2:  Design a binder from 
scratch. This strategy was 
advantageous because it created a 
large range of possibilities. This 
approach utilized de novo (computer) 
design and rotamer interaction field 
docking [2].  
The result of both strategies was a 
large quantity of possible 
minibinders. They were then tested 
to se how well they bind to the spike 
receptor binding domain. LCB1 and 
LCB3 were the miniproteins that 
showed the most neutralizing ability 





Moving Towards the Future
Dr. Baker and his lab use computer algorithms to design
synthetic proteins that may be beneficial in many different
applications. During the COVID-19 pandemic, he used his 
resources to try and find a way to stop coronavirus from infecting people and
reducing symptoms. This particular study shows that the developed computer
programs and models developed can quickly respond to a viral threat [1].
Ultimately, Dr. Baker’s ultimate goal is to be able to generate proteins with
these computer programs within weeks of obtaining the genome of a virus, 
which would streamline the workflow of experiments. If Baker’s online
design platforms keep improving, this goal is well within reach.
Benefits for the General Public
In this study, Dr. Baker and his lab “produced the most potent antivirals,
including LCB1, which is roughly six times more potent on a per mass basis
than the most effective monoclonal antibodies reported thus far” [3]. The
proteins that were designed also are much cheaper to commercially produce
than antibodies, with great stability and few temperature concerns [1]. These
are extremely valuable characteristics to mass vaccine production, seeing as
many people could be quickly and safely protected from COVID-19. 
Dr. Baker has a philosophy that the anyone has the ability to help accelerate
science from their own homes, even people who are not scientists. His labs
are extremely inclusive, and value the work that members of the community
do in the public access computer programs he developed (such as Foldit and
Rosetta@home) [4]. Seeing proteins designed by the public, can help Dr.
Baker and his lab move forward in the development of solutions to issues in
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